LivaNova

LIVN · NASDAQ

$80.90−$0.37 (−0.46%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $81.27

Latest news

Press releaseOct 23, 9:00 AM ETBusiness Wire
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
Press releaseOct 21, 9:00 AM ETBusiness Wire
LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
Press releaseSep 23, 9:00 AM ETBusiness Wire
LivaNova to Announce Third-Quarter 2026 Results
Press releaseSep 3, 9:00 AM ETBusiness Wire
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
NewsAug 5, 6:00 AM ET
LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate
Press releaseAug 5, 6:00 AM ETBusiness Wire
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Press releaseJun 24, 9:00 AM ETBusiness Wire
LivaNova to Announce Second-Quarter 2026 Results
Press releaseJun 16, 10:57 AM ETBusiness Wire
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
Press releaseJun 11, 1:44 PM ETBusiness Wire
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
Press releaseJun 5, 9:00 AM ETBusiness Wire
LivaNova Appoints Anne Liddy as Chief Legal Officer
Press releaseMay 21, 9:15 AM ETBusiness Wire
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
Press releaseMay 19, 8:00 AM ETBusiness Wire
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
NewsMay 6, 9:07 AM ET
LivaNova Q1 2026 Earnings Call Transcript
NewsMay 6, 6:19 AM ET
LivaNova Raises FY2026 Sales Guidance from $1.431B-$1.445B to $1.445B-$1.458B vs $1.494B Est
NewsMay 6, 6:06 AM ET
LivaNova Raises FY2026 Adj EPS Guidance from $4.15-$4.25 to $4.20-$4.30 vs $4.21 Est;
NewsMay 6, 6:03 AM ET
LivaNova Q1 Adj. EPS $0.98 Beats $0.90 Estimate, Sales $362.300M Beat $346.108M Estimate
Press releaseMay 6, 6:00 AM ETBusiness Wire
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Press releaseApr 20, 5:05 PM ETBusiness Wire
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
Press releaseMar 27, 10:15 AM ETPRNewswire
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
Press releaseMar 25, 9:00 AM ETBusiness Wire
LivaNova to Announce First-Quarter 2026 Results
Press releaseMar 19, 8:30 AM ETBusiness Wire
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
NewsFeb 25, 5:00 PM ET
5 Analysts Assess LivaNova: What You Need To Know
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
Press releaseFeb 25, 6:00 AM ETBusiness Wire
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
Press releaseJan 20, 9:00 AM ETBusiness Wire
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
Press releaseDec 23, 9:00 AM ETBusiness Wire
LivaNova to Present at J.P. Morgan Healthcare Conference in January
Press releaseDec 3, 9:00 AM ETBusiness Wire
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
Press releaseDec 2, 9:00 AM ETBusiness Wire
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
Press releaseNov 25, 9:00 AM ETBusiness Wire
LivaNova to Present at Piper Sandler Healthcare Conference in December
Press releaseNov 24, 9:00 AM ETBusiness Wire
LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
Press releaseNov 12, 3:26 PM ETBusiness Wire
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
Press releaseNov 5, 6:00 AM ETBusiness Wire
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
Press releaseAug 18, 9:00 AM ETBusiness Wire
LivaNova Launches Essenz Perfusion System in China
Press releaseAug 6, 6:00 AM ETBusiness Wire
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
Press releaseMay 7, 6:00 AM ETBusiness Wire
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
Press releaseFeb 25, 6:00 AM ETBusiness Wire
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
Press releaseOct 30, 6:00 AM ETBusiness Wire
LivaNova Reports Third-Quarter 2024 Results
NewsOct 4, 11:59 AM ETPriya Nigam
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Press releaseJul 31, 6:00 AM ETBusiness Wire
LivaNova Reports Second-Quarter 2024 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November

LivaNova to Announce Third-Quarter 2026 Results

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova to Announce Second-Quarter 2026 Results

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Jette Nygaard-Andersen Joins LivaNova Board as a New Director

LivaNova Appoints Anne Liddy as Chief Legal Officer

LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

Earnings Scheduled For May 6, 2026

LivaNova Q1 2026 Earnings Call Transcript

LivaNova Raises FY2026 Sales Guidance from $1.431B-$1.445B to $1.445B-$1.458B vs $1.494B Est

LivaNova Raises FY2026 Adj EPS Guidance from $4.15-$4.25 to $4.20-$4.30 vs $4.21 Est;

LivaNova Q1 Adj. EPS $0.98 Beats $0.90 Estimate, Sales $362.300M Beat $346.108M Estimate

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

LivaNova to Announce First-Quarter 2026 Results

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

5 Analysts Assess LivaNova: What You Need To Know

Earnings Scheduled For February 25, 2026

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

LivaNova to Present at J.P. Morgan Healthcare Conference in January

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

LivaNova to Present at Piper Sandler Healthcare Conference in December

LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

LivaNova Launches Essenz Perfusion System in China

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova Reports Third-Quarter 2024 Results

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

LivaNova Reports Second-Quarter 2024 Results